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Summary: Ergothioneine concentrations in the blood of 113 patients with diabetes mellitus and 22 non-
diabetic individuals were measured by high performance liquid chromatography. There is no statistically
significant difference between the mean ergothioneine concentrations of the diabetic and non-diabetic popu-
lations but there are several significant differences within the diabetic population. Male diabetics have a
higher ergothioneine concentration than female diabetics. Type II diabetics have a higher ergothioneine
concentration than type I diabetics. Diabetics receiving a higher insulin dose have higher ergothioneine
concentrations. There was no correlation of ergothioneine concentration with the concentration of haemoglo-
bin AI or with the number of years diabetic. It is suggested that zinc therapy may be beneficial for diabetics
having a high concentration of blood ergothioneine.
Introduction
Ergothioneine is the betaine of thiolhistidine which is
found ubiquitously in living organisms. It is thought
to be biosynthesized only in molds (1), but to accu-
mulate in many organisms as a result of its slow rate
of degradation (2). Ergothioneine can be in bound
form (3) in the plasma or liver, but is present in free
form (1—3) in erythrocytes and many-tissues. It has
been reported that diabetic patients have a signifi-
cantly higher concentration of ergothioneine in their
erythrocytes (0.127 g/1) than normal individuals (0.096
g/1), with 16% of diabetics exceeding the highest con·̂
centration (0.177 g/1) found in normal individuals and
reaching concentrations as high as 0.60 g/1 (4). This
elevation of ergothioneine concentrations is not just
a result of the diabetic state, since no rise in ergothi-
oneine concentrations is observed in rats made dia-
betic with alloxan (5). However, depancreatized rats
have decreased red blood cell ergothioneine, suggest-
ing a relationship between pancreatic function and
ergothioneine pharmacodynamics (5). Ergothioneine
concentrations have also been associated with the
formation of cataracts, since cataractous human lens
has a lower ergothioneine content than normal lens
(6).
The possible role of ergothioneine in health and dis-
ease has received little attention (7). One of the chem-
ical properties of ergothioneine which suggests that it
might have biological effects is its ability to form
complexes with divalent metal ions (8), although it
would generally bind less metal ions than glutathione
(9). It has been suggested that the chelation properties
of ergothioneine could be important in the develop-
ment of diabetes mellitus (10). Trace metals can reg-
ulate insulin release (11) as well as having insulin-like
action (12) in the whole animal. Several studies have
shown effects of ergothioneine on biological systems
both in vitro and in vivo. Ergothioneine inhibits the
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degradation of insulin by a liver extract (13). It in-
hibits the activity of polyphenol oxidases (8), papain
(14) and the ATPase activity of myosin in the absence
of divalent cations (14). Ergothioneine inhibits lipid
peroxidation in mouse liver homogenates (15). It ac-
celerates the oxidation of reduced nicotinamide ad-
enine dinucleotide by metmyoglobin or methaemoglo-
bin (16). Ergothioneine also accelerates lactate for-
mation in red blood cells (17) and reduced the pen-
tobarbital sleeping time and inhibited hepatic injury
(18). Ergothioneine protects against cadmium-in-
duced teratogenesis (19).
Because of the variety of biological effects that have
been demonstrated for ergothioneine and because of
the previous association that had been demonstrated
between blood ergothioneine concentrations and di-
abetes mellitus (4), it was decided to investigate this
relationship further. In the original work of Fr ser, a
colorimetric method based on the diazotization of
ergothioneine was used (4). Recently, with the devel-
opment of high performance liquid chromatography
(HPLC)1, a more specific and sensitive method for
the determination of ergothioneine became available
(2). We have used HPLC methodology to determine
ergothioneine concentrations, primarily in diabetics,
and evaluated if there is a correlation between these
concentrations and other indices such as age, sex,
haemoglobin Aj (HbAi) concentrations and class of
diabetes.
Methods
Human blood specimens, which had been taken for diagnostic
purposes, were used. The blood samples were collected in va-
cutainers with EDTA as anticoagulant. Glycosylated haemo-
globin (HbAO was determined by the Isolab microcolumn pro-
cedure (20). For ergothioneine determinations the blood sam-
ples were diluted 1:3 with distilled water, placed in a boiling
water bath for 15 minutes and then centrifuged for 15 minutes
at top speed in a clinical centrifuge. A measured aliquot of
variable volume of the supernate was withdrawn and lyophi-
lized. The dried residue was taken up in aqueous ethanol,
volume fraction 0.5, and filtered through a 0.2 micron Gelman
Aero LC13 filter assembly. Twenty to 100 μΐ were injected onto
a 4 χ 300 mm μ Bondapak NH2 column with a guard column
containing Bondapak AX/Corasil (Waters Associates, Milford,
MA). The column was eluted with acetonitrile and water
(80 + 20 by volume). A Varian Model 5560 HPLC instrument,
fitted with a UV-200 scanning detector and a Model 8085 auto
sampler, was used. The detector was set at 258 nm (the ab-
sorbance maximum of ergothioneine), and the How rate set at
1 ml/min. Ergothioneine was eluted at about 18 min as a distinct
peak, well resolved from other peaks in the chromatograms.
After the complete elution of ergothioneine, the acetonitrile,
water (80 + 20 by volume) mixture was run for an additional
15 minutes to wash the column. After a number of runs, the
column was washed with acetonitrile in water, volume fraction
0.5 and/or with pure acetonitrile followed by re-equilibration
with the acetonitrile, water (80 + 20 by volume). A standard
curve with 0.1 to 2 μg of ergothioneine (Sigma Chem. Co., St.
Louis, MO) was made and found to l?e linear. This standard
curve was used to calculate the amount of ergothioneine in our
samples using the Varian 4270 integrator. Quantitative recovery
(> 95%) of ergothioneine from aqueous solutions or added to
blood samples was found after boiling, lyophilizing and redis-
solving in aqueous ethanol, volume fraction 0.5. Similar results
were found by Mayumi et al. (2), after whose work our method
was adapted.
Statistical analysis was performed on an IBM-PC computer
using the PC Statistician software package (Human Systems
Dynamics, Northridge, CA). Frequency distributions were first
obtained. Ergothioneine concentrations for diabetics do not
follow a normal distribution. Statistical significance was eval-
uated using the non-parametric Mann-Whitney U test for this
group but the Student t-test for the non-diabetic population
which showed a normal distribution. The precision of our















HPLC, high performance liquid chromatography,
HbA,, haemoglobin AI,
S.E.M., standard error of the mean.
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Fig. 1. Distribution of ergothioneine values in blood for the
total diabetic population (n = 113).
Results
The frequency distribution of the blood ergothioneine
concentrations of diabetic individuals shows a non-
normal distribution (fig. 1). Table 1 summarizes the
results of our determinations of ergothioneine and the
HbAj concentrations for various categories of indi-
viduals. Although the difference between the ergothi-
oneine concentrations in the total population of di-
abetics vs the non-diabetic population is not signifi-
cant (p > 0.05), there are several statistically signifi-
cant correlations within the diabetic population. The
number of samples in several categories does not
always add up to the total number of subjects tested,
as some information, such as age, sex or type of
diabetes, etc., was not available for some individuals.
Diabetic males have significantly higher ergothioneine
concentrations than diabetic females although there
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*p calculated using the Mann-Whitney U test for comparing the ergothioneine Values for different pairs of groups, except for
non-diabetics for which the Student t-test was used.
** From I.e. (20).
is no correlation with sex for the smaller non-diabetic
population. When the diabetic population is separated
into type I and type II and males are compared with
females for each of these groups the sex difference is
no longer statistically significant (p > 0.05). However,
type II males have higher ergothioneine concentra-
tions than type I males but this is not the case for
type I vs type II females (tab. 1). There is no signifi-
cant difference between diabetic vs non-diabetic
males, diabetic vs non-diabetic females or type II
diabetic males vs non-diabetic males (p > 0.05). Type
II diabetics also have ergothioneine concentrations
which are higher than those of type I diabetics (tab.
1). The HbAj concentrations for all of the groups of
diabetics are significantly above the average expected
for normal individuals and by approximately the same
amount (tab. 1). The data for the entire diabetic
population were further analyzed by a least-squares
linear regression analysis to find the correlation be-
tween ergothioneine concentrations and other varia-
bles (tab. 2). There was a weak correlation between
ergothioneine concentrations and either insulin dose
or age which showed some statistical significance. This
was further analyzed by comparing different groups
of subjects using the Mann-Whitney U test. Diabetics
below the age of 20 had lower ergothioneine concen-
trations than older diabetics although there was no
significant difference among diabetics in the 20—40,
40—60 and 60 and above age groups nor was there
an age dependence for the smaller non-diabetic pop-
ulation. All but one of the diabetics in the 0—20 age
group was a type I diabetic. We have already shown
that type I diabetics have a lower ergothioneine con-
centration than type II diabetics (tab. 1). There is no
statistically significant difference between type I dia-
betics below the age of 20 compared to type I diabetics
above the age of 20. Therefore, the correlation of
ergothioneine concentration with age for diabetics is
at least partially a consequence of the difference be-
tween type I and type II diabetics. Diabetics receiving
less than 40 units of insulin per day had lower ergo-
thioneine concentrations than those receiving larger
insulin doses (tab. 1). The group receiving the lower
insulin dose did not have a statistically significant
difference in their mean HbAi concentration, age or
sex compared with the group receiving the higher
insulin dosage (all are type I diabetics).
Tab. 2. Correlation of ergothioneine concentrations for the en-
tire diabetic population and HbAi concentration, in-






















Type I diabetics only.
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Discussion
The average ergothioneine concentrations measured
by HPLC are generally lower than those reported by
Fräser (4). This is probably due to the lower specificity
of the colorimetric procedure (1) used in the previous
work (4). Nevertheless, some of our general conclu-
sions confirm the work of Fräser in that there is a
significant fraction of diabetics whose ergothioneine
concentrations are higher than the modal value (fig.
1). We can further specify that among diabetics, males,
type II diabetics and diabetics taking a higher insulin
dose have higher ergothioneine concentrations than
their diabetic counterparts, i.e. females, type I di-
abetics and diabetics taking a lower insulin dose. It
is possible that the management of diabetics with high
ergothioneine concentrations could be aided with the
administration of dietary zinc (10). Zinc is important
for the storage of insulin and for the metabolism of
arachidonic acid. Zinc insufficiency can lead to glu-
cose intolerance. Since ergothioneine binds zinc, it
can limit the availability of this cation and thereby
aggravate the diabetic state. This situation would
occur only in those diabetics with markedly elevated
concentrations of ergothioneine: For patients in this
group, zinc therapy may have some efficacy.
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